MARKET

FWBI

FWBI

First Wave Biopharma Inc
NASDAQ
1.650
+0.020
+1.23%
Pre Market: 1.650 0 -0.02% 09:04 10/05 EDT
OPEN
1.670
PREV CLOSE
1.630
HIGH
1.740
LOW
1.596
VOLUME
25
TURNOVER
--
52 WEEK HIGH
106.50
52 WEEK LOW
1.190
MARKET CAP
2.29M
P/E (TTM)
-0.0113
1D
5D
1M
3M
1Y
5Y
Why Carnival Shares Are Trading Lower By 19%, Here Are 49 Stocks Moving In Friday's Mid-Day Session
Gainers
Benzinga · 4d ago
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Ainos (NASDAQ:AIMD) shares increased by 46.4% to $2.02 during Friday's pre-market session. The market value of their outstanding shares is at $39.3 million.
Benzinga · 5d ago
GFRS, FWBI and SSNT are among pre market gainers
Ainos (AIMD) +46% <a href="https://seekingalpha.com/pr/18959068-ainos-announces-posi...
Seekingalpha · 5d ago
Why Amylyx Pharmaceuticals Is Trading Higher By Over 8%; Here Are 22 Stocks Moving Premarket
Gainers SAI.TECH Global Corporation (NASDAQ: SAI) rose 42% to $3.21 in pre-market trading after dipping 26% on Thursday. SAI.TECH recently announced the launch of new liquid cooling Bitcoin mining infrastructure products.
Benzinga · 5d ago
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers
Benzinga · 5d ago
First Wave BioPharma’s CEO James Sapirstein to Present at Inaugural Roth Healthcare Opportunities Conference
BOCA RATON, Fla., Sept. 28, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for g...
GlobeNewswire · 09/28 11:00
First Wave BioPharma extends selloff after announcing strategic shift
Micro-cap biotech First Wave BioPharma (NASDAQ:FWBI) c...
Seekingalpha · 09/19 17:29
BRIEF-First Wave Biopharma To Direct Resources For Filing IND & Mid-Stage Study Of Adrulipase Formulation
BRIEF-First Wave Biopharma To Direct Resources For Filing IND & Mid-Stage Study Of Adrulipase Formulation
Reuters · 09/19 11:16
More
About FWBI
First Wave BioPharma, Inc. is engaged in the research and development of targeted, non-systemic therapies for the treatment for gastrointestinal (GI) diseases. The Company is focused on developing its pipeline of gut-restricted GI clinical product candidates, including niclosamide, which is an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, which is a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. The Company is advancing two separate clinical programs of niclosamide formulations, both of which are in Phase II clinical trials, including FW-COV for Severe Acute Respiratory Syndrome Coronavirus 2 GI infections, and FW-UP for ulcerative proctitis and ulcerative proctosigmoiditis. The adrulipase programs is focused on the development of an oral, non-systemic, biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis.

Webull offers kinds of First Wave BioPharma Inc stock information, including NASDAQ:FWBI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FWBI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FWBI stock methods without spending real money on the virtual paper trading platform.